Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Cost of sales as % of net product revenues by Quarter
Cost of sales as % of net product revenues (%) (%)
Vertex Pharmaceuticals Cost of sales as % of net product revenues: 14.7% in Q2 2026, up 0.9 pts from a year earlier. That is the highest of the 26 quarters on record here.
Where the Q2 2026 figure comes from
“Our cost of sales as a percentage of our net product revenues increased to 14.7% in the second quarter of 2026 as compared to 13.8% in the second quarter of 2025 , as a result of changes in product mix, partially offset by a lower blended royalty rate for our CF medicines.”
Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K MD&A (Cost of Sales Table).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Cost of sales as % of net product revenues (%), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cogs-pct-prod-rev
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.